Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin

Digestion

Volumn 85, Issue 1, 2012, Pages 9-17

  Sugimoto, Mitsushige ^a   Nishino, Masafumi ^a   Kodaira, Chise ^a   Yamade, Mihoko ^a   Uotani, Takahiro ^a   Ikuma, Mutsuhiro ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aspirin; Famotidine; Gastroesophageal reflux disease; Lansoprazole; Non steroidal anti inflammatory drugs; Rabeprazole

Indexed keywords

ACETYLSALICYLIC ACID; BAYASPIRIN; FAMOTIDINE; LANSOPRAZOLE; RABEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; GASTROINTESTINAL ENDOSCOPY; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ASPIRIN; CROSS-OVER STUDIES; ESOPHAGUS; FAMOTIDINE; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HUMANS; MALE; MUCOUS MEMBRANE; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82055175128     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000329295     Document Type: Article

References (34)

1. Awtry EH, Loscalzo J: Aspirin. Circulation 2000; 101: 1206-1218.
2. Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099. (Pubitemid 30482713)
3. Derry S, Loke YK: Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-1187.
4. Weil J, Colin-Jones D, Langman M, et al: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-830.
5. Nishino M, Sugimoto M, Kodaira C, et al: Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci 2010;55:1627-1636.
6. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al: Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-167. (Pubitemid 24225631)
7. Nasseri-Moghaddam S, Mofid A, Ghotbi MH, et al: Epidemiological study of gastrooesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther 2008; 28: 144-153. (Pubitemid 351782814)
8. Kusano M, Shirai N, Yamaguchi K, et al: It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole - a report from a study with Japanese patients. Dig Dis Sci 2008; 53: 3082-3094.
9. Miwa H, Sasaki M, Furuta T, et al: Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 2007; 26: 69-77. (Pubitemid 46889840)
10. Sugimoto M, Nishino M, Kodaira C, et al: Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. J Clin Pharmacol 2010; 50: 320-330.
11. Bell NJ, Burget D, Howden CW, et al: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(suppl 1):59-67.
12. Lanas A, Hirschowitz BI: Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol 1991; 13: 622-627.
13. Ryan P, Hetzel DJ, Shearman DJ, et al: Risk factors for ulcerative reflux oesophagitis: a case-control study. J Gastroenterol Hepatol 1995; 10: 306-312.
14. Avidan B, Sonnenberg A, Schnell TG, et al: Risk factors of oesophagitis in arthritic patients. Eur J Gastroenterol Hepatol 2001; 13: 1095-1099. (Pubitemid 32905205)
15. Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, et al: Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther 2004; 19: 95-105. (Pubitemid 38125642)
16. Ruigomez A, Garcia Rodriguez LA, Wallander MA, et al: Natural history of gastrooesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther 2004; 20: 751-760. (Pubitemid 39319230)
17. Ruszniewski P, Soufflet C, Barthelemy P: Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther 2008; 28: 1134-1139.
18. Taha AS, McCloskey C, Prasad R, et al: Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119-125.
19. Berlin RG, Root JK, Cook TJ: Nocturnal therapy with famotidine for one year is effective in preventing relapse of gastric ulcer. Aliment Pharmacol Ther 1991; 5: 161-171.
20. Valenzuela JE, Kogut DG, McCullough AJ, et al: Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study. Am J Gastroenterol 1996; 91: 2516-2522.
21. Shimatani T, Inoue M, Kuroiwa T, et al: Acidsuppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther 2006; 79: 144-152. (Pubitemid 43069585)
22. Lanza FL, Royer GL Jr, Nelson RS, et al: A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 1981; 75: 17-21. (Pubitemid 11106121)
23. Naito Y, Yoshikawa T, Iinuma S, et al: Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci 1998; 43: 83S-89S. (Pubitemid 28433955)
24. Miki K, Ichinose M, Ishikawa KB, et al: Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993; 84: 1086-1090. (Pubitemid 23307845)
25. De Morais SM, Goldstein JA, Xie HG, et al: Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-411.
26. De Morais SM, Wilkinson GR, Blaisdell J, et al: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598. (Pubitemid 24334747)
27. Lanas AI, Sousa FL, Ortego J, et al: Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur J Gastroenterol Hepatol 1995; 7: 1065-1072. (Pubitemid 26014462)
28. El-Serag HB, Sonnenberg A: Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1997; 92: 52-56. (Pubitemid 27027028)
29. Voutilainen M, Sipponen P, Mecklin JP, et al: Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61: 6-13. (Pubitemid 30098953)
30. Kotzan J, Wade W, Yu HH: Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res 2001; 18: 1367-1372. (Pubitemid 32846334)
31. Orland R: Oesophageal mucosal resistance. Aliment Pharmacol Ther 1998; 12: 191-197.
32. Semble EL, Wu WC, Castell DO: Nonsteroidal anti-inflammatory drugs and esophageal injury. Semin Arthritis Rheum 1989; 19: 99-109. (Pubitemid 19269475)
33. Poplawski C, Sosnowski D, Szaflarska-Poplawska A, et al: Role of bile acids, prostaglandins and COX inhibitors in chronic esophagitis in a mouse model. World J Gastroenterol 2006; 12: 1739-1742.
34. Triadafilopouloa G, Kaur B, Sood S, et al: The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E 2 production in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2006; 23: 997-1005.